MedTrace Logo

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

NCT00604760 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2008-12-08

No results posted yet for this study

Summary

To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).

Conditions

  • Cognitive Impairment Associated With Schizophrenia

Interventions

DRUG

MEM 3454

Capsule 5 mg once a day

DRUG

MEM 3454

Capsule 15 mg once a day

DRUG

MEM 3454

Capsule 50 mg once a day

DRUG

Placebo for MEM 3454

Capsule once a day

Sponsors & Collaborators

  • Memory Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604760 on ClinicalTrials.gov